# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with...
- SEC Filing
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target f...
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12...
HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.
Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants fo...